Denmark's Lundbeck has said that efforts to build its R&D portfolio are on track to deliver four new molecular entities (NMEs ...

Pharmaceuticals and Sobi announced that results from the Phase 3 VALIANT study were presented as an oral presentation during the High-Impact Clinical Trials session at the American Society of ...

Bitcoin’s (BTC) price has climbed 55% so far in 2024, including 12.50% gains in October. Its recent increases have been ...

Crypto.com Arena, which celebrated its 25th anniversary this month, has completed phase three of its nine-figure, ...

Enterprises are poised to take artificial intelligence to the next level, building on initial forays into AI that mostly ...

NIOSH has awarded three innovative solutions for improving real-time respirator fit evaluation as part of its $350,000 ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on ...

Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease statusConfirmatory data to ...

BriaCell Therapeutics could access a $1-$5 billion market upon approval despite a sub-$30 million cap. See more on BRIA stock ...

Otsuka Pharmaceutical’s kidney disease drug has hit the primary endpoint of a phase 3 trial by demonstrating in an interim ...

The Eagles' young DBs will certainly be tested Sunday against the Cincinnati Bengals behind quarterback Joe Burrow and his ...

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that initial safety and ...